UCB, Others Sue 15 Generics Makers For Violating Vimpat Drug Patent
This article was originally published in PharmAsia News
Glenmark, Ranbaxy Laboratories, Sun Pharma and other India drug makers are among 15 sued in a U.S. federal court for violating the patent of the epilepsy drug Vimpat (lacosamide) licensed to UCB.
You may also be interested in...
The US FDA appears poised to release long-promised regulations on lab-developed tests. However, some industry observers still have doubts as to whether the agency is truly prepared.
The agency’s committees for Risk Assessment and Socio-Economic Analysis will check comments and take relevant evidence-based information into consideration as they develop their opinions. Final opinions will be delivered to the European Commission “in the shortest possible timeframe,” ECHA says.
After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.